319 related articles for article (PubMed ID: 33615993)
1. Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response.
Mohseni AH; Casolaro V; Bermúdez-Humarán LG; Keyvani H; Taghinezhad-S S
Gut Microbes; 2021; 13(1):1-17. PubMed ID: 33615993
[TBL] [Abstract][Full Text] [Related]
2. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
[TBL] [Abstract][Full Text] [Related]
5. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
8. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
Chen Z; Yang L; Liu Y; Tang A; Li X; Zhang J; Yang Z
Mol Cell Biochem; 2014 Jan; 385(1-2):169-77. PubMed ID: 24072614
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
10. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.
Roy T; Boateng ST; Uddin MB; Banang-Mbeumi S; Yadav RK; Bock CR; Folahan JT; Siwe-Noundou X; Walker AL; King JA; Buerger C; Huang S; Chamcheu JC
Cells; 2023 Jun; 12(12):. PubMed ID: 37371141
[TBL] [Abstract][Full Text] [Related]
11. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
12. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
14. Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer.
Meuten TK; Dean GA; Thamm DH
Vet Pathol; 2024 May; 61(3):339-356. PubMed ID: 37905509
[TBL] [Abstract][Full Text] [Related]
15. Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization.
Thaa B; Biasiotto R; Eng K; Neuvonen M; Götte B; Rheinemann L; Mutso M; Utt A; Varghese F; Balistreri G; Merits A; Ahola T; McInerney GM
J Virol; 2015 Nov; 89(22):11420-37. PubMed ID: 26339054
[TBL] [Abstract][Full Text] [Related]
16. Encouraging Tactics with Genetically Modified Probiotics to Improve Immunity for the Prevention of Immune-Related Diseases including Cardio-Metabolic Disorders.
Asai T; Yoshikawa S; Ikeda Y; Taniguchi K; Sawamura H; Tsuji A; Matsuda S
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671395
[TBL] [Abstract][Full Text] [Related]
17. Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade.
Nurcahyanti ADR; Jap A; Lady J; Prismawan D; Sharopov F; Daoud R; Wink M; Sobeh M
Biomed Pharmacother; 2021 Dec; 144():112138. PubMed ID: 34750026
[TBL] [Abstract][Full Text] [Related]
18. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
Popova NV; Jücker M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders.
Chen J; Alberts I; Li X
Int J Dev Neurosci; 2014 Jun; 35():35-41. PubMed ID: 24662006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]